This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

GlaxoSmithKline PLC (GSK)

NYSE: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) 9.28B 7.67B 8.47B 2.86B
Operating Gains/Losses -2.92B 2.02B -1.29B 2.77B
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -333.10M 252.10M 190.97M 1.41B
(Increase) Decrease in Inventories -156.65M 59.79M -243.76M 367.33M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 206.12M 286.03M 686.25M 237.68M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 -3.39B 2.55B
(Increase) Decrease In Other Working Capital 375.97M -4.52B 3.11M -276.27M
Other Non-Cash Items 3.12B 1.68B 3.06B -2.02B
Net Cash From Continuing Operations 11.91B 7.07B 9.70B 10.49B
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 11.91B 7.07B 9.70B 10.49B
Sale of Property, Plant & Equipment 300.12M 1.82B 523.23M 336.46M
Cash Used for Investing Activities
Sale of Short-Term Investments 24.73M 0.00 46.58M 140.45M
Purchases of Property, Plant & Equipment -2.80B -2.46B -2.06B -2.52B
Acquisitions 2.64B -3.61B -409.89M -546.36M
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 126.97M 114.74M 1.68B 192.93M
Cash Provided by Financing Activities
Net Cash From Investing Activities 864.07M -4.25B -173.89M -2.88B
Issuance of Debt 3.15B 9.98B 69.87M 9.26M
Cash Used for Financing Activities
Issuance of Capital Stock 964.66M 669.03M 458.02M 121.93M
Repayment of Long-Term Debt -3.09B -4.19B -71.42M -2.07B
Repurchase of Capital Stock -2.55B -4.09B -3.46B -24.69M
Payment of Cash Dividends -6.07B -6.44B -5.65B -4.95B
Other Financing Charges, Net -2.75B -1.34B -1.02B -1.69B
Net Cash From Financing Activities -10.34B -5.42B -9.68B -8.60B
Effect of Exchange Rate Changes -244.05M -148.67M -167.68M 125.02M
Net Change in Cash & Cash Equivalents 2.18B -2.75B -313.63M -865.85M
GSK News

GSK GlaxoSmithKline PLC

Analysts Ratings for GSK

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 2 2
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 1 1 0 0
GET GSK ANALYST REPORT

Brokerage Partners

GSK Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs